Skip to main content
ADIL
NASDAQ Life Sciences

Adial's Q2 Loss of $52M and Cash Runway into 2H 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$3.08
Mkt Cap
$8.71M
52W Low
$1.31
52W High
$10.75
52W Position info
135% above low
Off High info
71% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

ADIL has more than doubled off its 52-week low of $1.31 on light trading volume (0.1× avg).

Summary

Adial Pharmaceuticals posted a Q2 net loss of $52 million, largely due to a non-cash $46.2 million acquired R&D charge, while $28.7 million in cash supports operations into 2H 2027.


Key Events · Earnings and Guidance · ADIL

  • Q2 Net Loss of $52M

    A net loss of $52.0 million, or $11.25 per share, was driven by a $46.2 million non-cash acquired in-process R&D charge from the Azora acquisition.

  • Cash Runway into 2H 2027

    Cash and equivalents stood at $28.7 million as of June 30, 2026, up from $4.6 million at March 31, 2026, funding operations into the second half of 2027 excluding the $32 million milestone tranche.

  • Stockholders' Deficit of $38.4M

    The deficit includes a $23.8 million milestone warrant liability and $38.5 million mezzanine equity from Series A convertible preferred stock, both expected to reclassify to equity upon stockholder approval.

  • AT177 IND Filing Planned 1H 2027

    Lead program AT177, an oral AhR agonist for ulcerative colitis, is on track for an IND filing in the first half of 2027, with a Phase 1a trial planned for the second half of 2027.


Analysis · ADIL · Life Sciences

The second quarter delivered a $52 million net loss for Adial, driven by a $46.2 million non-cash charge for acquired in-process R&D from the Azora merger. With $28.7 million in cash, operations are funded into the second half of 2027, excluding a potential $32 million milestone tranche. A stockholders' deficit of $38.4 million and a Nasdaq listing deficiency weigh on the balance sheet, but the financing and pipeline progress offer a path forward.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADIL was trading at $3.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $1.31 to $10.75. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADIL - Latest Insights

ADIL
Nov 12, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: $0 (0%) info
Market Cap: $13.261M info
ADIL
Nov 12, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: $0 (0%) info
Market Cap: $13.261M info
ADIL
Nov 09, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: $0 (0%) info
Market Cap: $13.261M info
ADIL
Oct 28, 2026, 5:56 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.08
Real-time Price: $4.86 info
Change: -$0.220 (-4%) info
Market Cap: $13.261M info
ADIL
Oct 28, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: -$0.0036 (-0.07%) info
Market Cap: $13.261M info